Annex A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MA (EU) number 
(Invented) 
name 
Strength 
Pharmaceutical 
Form 
Route of 
Administration 
Immediate 
Packaging 
Content 
(concentration) 
Pack size 
EU/1/20/1503/001  HEPLISAV B   
EU/1/20/1503/002  HEPLISAV B 
--¹ 
--¹ 
Solution for 
injection 
Solution for 
injection 
Intramuscular use  pre-filled syringe 
0.5 ml (40 µg/ml) 
5 syringes  
Intramuscular use  Pre-filled syringe 
0.5 ml (40 µg/ml) 
1 syringe 
(glass) 
(glass) 
--¹ 
--¹  
One dose (0.5 ml) contains: 
Hepatitis B surface antigen¹,²                20 µg 
¹Adjuvanted with 3000 micrograms cytidine phosphoguanosine (CpG) 1018 adjuvant, a 22-mer phosphothioate oligonucleotide (PS-ODN) comprising 
microbial DNA-like unmethylated CpG motifs 
²Produced in Hansenula polymorpha yeast cells by recombinant DNA technology 
EMA/178491/2023  
 
 
 
 
 
 
